KymaThera Secures $80 Million in Series B Funding Led by Alta Partners

KymaThera Raises $80 Million in Series B Funding

KymaThera, a biotechnology company based in San Diego, California, has announced the successful closure of its Series B funding round, raising $80 million. The round was led by Alta Partners, with participation from Venrock, Foresite Capital, and J. Wood Capital.

KymaThera focuses on developing innovative therapies for cancer treatment, aiming to provide new options for patients with unmet medical needs. Rob Kania, CEO and Co-founder, stated, "This funding will accelerate the development of our pipeline and bring us closer to offering new treatment options for patients."

Lead Investor and Participants

Alta Partners served as the lead investor in this funding round. The involvement of other notable investors such as Venrock, Foresite Capital, and J. Wood Capital underscores the confidence in KymaThera's potential to make significant advancements in oncology.

Use of Funds

The newly secured funds are expected to be used to advance KymaThera's research and development efforts, particularly in expanding its pipeline of oncology therapies. The company plans to enhance its clinical trials and potentially increase its workforce to support these initiatives.

KymaThera's latest funding round marks a significant milestone in its journey to develop novel treatments that could transform the landscape of cancer care.